Recombinant Human VEGF 165 Protein, BSA (E.coli)

Human

No tag

20 kDa

20 kDa, reducing conditions

>95% as determined by Bis-Tris PAGE.

< 0.1 EU/ug by the LAL method

Lyophilized from a 0.22 μm filtered solution in PBS with BSA as a carrier protein. Normally 8% trehalose is added as protectant before lyophilization.

For long-term storage, keep the product lyophilized at -20°C or below. Please avoid repeated freeze-thaw cycles. Stability:​ Lyophilized: 12 months (-20°C to -80°C) Reconstituted: 3 months at -80°C under sterile conditions.

NP_001165097, P15692-4

growth factor; H-VEGF-165; L-VEGF; M-VEGF-165; vascular endothelial growth factor; Vascular endothelial growth factor A, long form; vascular endothelial growth factor A165; Vascular permeability factor; vascular permeability factor precursor; VEGF165; VPF; L-VEGF; MVCD1; VEGF; VEGFA; VPF

VEGF-165 是血管内皮生长因子A（VEGF-A）最主要的剪接变体。它由多种细胞产生，包括血管内皮细胞、巨噬细胞和T细胞。VEGF-165 参与血管生成、调控血管内皮细胞的存活、生长、迁移以及血管通透性。VEGF基因的表达受缺氧、炎症细胞因子和癌基因诱导。VEGF-165可与硫酸乙酰肝素结合，从而滞留于细胞表面和细胞外基质中。它还与受体酪氨酸激酶VEGFR1和VEGFR2结合。独特的是，VEGF-165是唯一能够与辅助受体神经纤毛蛋白-1（NRP-1）和神经纤毛蛋白-2（NRP-2）结合的剪接变体，这些辅助受体起到增强VEGFR2信号通路的作用。VEGF-165与VEGFR1和VEGFR2的结合，可激活包括PI3K/Akt、p38 MAPK、黏着斑激酶和桩蛋白在内的多条信号通路。VEGF在多种癌症的肿瘤血管生成过程中扮演关键角色。